All Updates

All Updates

icon
Filter
Funding
Celsius raises combined funding of USD 83 million
Precision Medicine
Mar 24, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Mar 24, 2022

Celsius raises combined funding of USD 83 million

Funding

  • Biotech precision medicine drug developer Celsius Therapeutics has raised USD 83 million in total funding from an extension of a Series A funding round, previously announced in May 2018, and a Series B round. The company received funding from new and existing investors including Casdin Capital, GV, Heritage Provider Network, Amgen Ventures, and Amplitude Ventures. 

  • The funds will be invested in its investigational new drug (IND) filing with the FDA for its first drug candidate CEL383, an antibody treatment for inflammatory bowel disease, followed by a Phase 1 clinical trial in early 2023. The funds will also support the company’s plans to expand its oncology pipeline using its SCOPE platform to discover drug targets.

  • Celsius currently has two drug discovery programs in oncology in partnership with independent pharma group Servier.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.